Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Key Inclusion Criteria:

• Male or female, of any race, at least 18 years of age (inclusive).

• Freely provides both verbal and written informed consent.

• Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA ofat least 3%, but no more than 12%. The face, scalp, palms, soles, axillae andintertriginous areas are to be excluded in this calculation.

• Is willing and able to avoid prolonged exposure of the treatment area to ultravioletradiation (natural and artificial) for the duration of the study.

• Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or

4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excludedin this assessment).

Key Exclusion Criteria:

• Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustularpsoriasis, as determined by the investigator.

• Presents with psoriasis that was treated with prescription medication and failed torespond to treatment, even partially or temporarily, as determined by theinvestigator.

• Presents with any concurrent skin condition that could interfere with the evaluationof the treatment areas, as determined by the investigator.

• Is pregnant, nursing an infant, or planning a pregnancy during the study period.

• Has received treatment with any investigational drug or device within 60 days or 5drug half lives (whichever is longer) prior to the Baseline visit, or is concurrentlyparticipating in another clinical study with an investigational drug or device.